In continuation of my update on omega-3-fatty-acids
Unequivocal evidence that omega-3 fatty acids reduce breast cancer risk
Unequivocal evidence that omega-3 fatty acids reduce breast cancer risk
Med-Chemist : "Quintessential Medicinal Chemistry"
Tuesday, February 26, 2013
Monday, February 25, 2013
Sunday, February 24, 2013
Meloxicam recognizes and treats osteoarthritis in cats
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and fever reducer effects. It is a derivative of oxicam, closely related to piroxicam, and falls in the enolic acid group of NSAIDs. It was developed by Boehringer-Ingelheim.
Saturday, February 23, 2013
Resistant starch kills pre-cancerous cells and reduces inflammation
Resistant starch (RS) is starch and starch degradation products that escape digestion in the small intestine of healthy individuals. Resistant starch is considered the third type of dietary fiber, as it can deliver some of the benefits of insoluble fiber and some of the benefits of soluble fiber.
Some carbohydrates, such as sugars and most starch, are rapidly digested and absorbed as glucose
into the body through the small intestine and subsequently used for
short-term energy needs or stored. Resistant starch, on the other hand,
resists digestion and passes through to the large intestine where it acts like dietary fiber.
More...
More...
Friday, February 22, 2013
Thursday, February 21, 2013
New Antibiotic May Treat Skin Infections in Shorter Time - Drugs.com MedNews
Torezolid (also known as TR-701 and now tedizoli) is an oxazolidinone drug being developed by Trius Therapeutics(originator Dong-A Pharmaceuticals) for complicated skin and skin-structure infections (cSSSI), including those caused by Methicillin-resistant Staphylococcus aureus (MRSA).
Tuesday, February 19, 2013
Monday, February 18, 2013
Breakthrough in ovarian cancer: Selumetinib
In continuation of my update on Seumetinab
Ref : http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70572-7/fulltext
Breakthrough in ovarian cancer: Selumetinib
We know that, Selumetinib (AZD6244) is a drug being investigated for the treatment of various types of cancer, for example non-small cell lung cancer (NSCLC).
Mode of action : The gene BRAF is part of the MAPK/ERK pathway, a chain of proteins in cells that communicates input from growth factors. Activating mutations in the BRAF gene, primarily V600E (meaning that the amino acid valine in position 600 is replaced by glutamic acid), are associated with lower survival rates in patients with papillary thyroid cancer. Another type of mutation that leads to undue activation of this pathway occurs in the gene KRAS and is found in NSCLC. A possibility of reducing the activity of the MAPK/ERK pathway is to block the enzyme MAPK kinase (MEK), immediately downstream of BRAF, with the drug selumetinib. More specifically, selumetinib blocks the subtypes MEK1 and MEK2 of this enzyme....
The study was initially developed in 2007, with 52 patients enrolled for the Phase II clinical trial between December 2007 and November 2009. Patients were given 50 milligrams of selumetinib orally twice daily. Of those participants, eight had a measurable decrease in tumor size, seven had partial responses and 34 patients saw their tumors stabilize. The findings suggest that inhibitors of the MAPK pathway warrant further investigation in patients with low-grade ovarian cancer.
"There just aren't very good treatments for low-grade ovarian cancer, so this discovery opens up a lot of new exciting possibilities for us," Dr. Farley said. He added that Phase III of this trial is scheduled to begin in the next few weeks, with that trial to be the "definitive test" before the treatment becomes available to the general population.
Breakthrough in ovarian cancer: Selumetinib
Sunday, February 17, 2013
Saturday, February 16, 2013
FDA Approves Pomalyst for Advanced Multiple Myeloma
We know that, Pomalidomide (INN, originally CC-4047 or 3-amino-thalidomide, marketed as Pomalyst by Celgene), is a derivative of thalidomide that is anti-angiogenic and also acts as an immunomodulator. Pomalidomide was approved on February 8, 2013 by the U.S. Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma....
Friday, February 15, 2013
FDA Approves Ravicti for the Chronic Management of Some Urea Cycle Disorders
The U.S. Food and Drug Administration today approved Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients ages 2 years and older.
UCDs are genetic disorders that involve deficiencies of specific enzymes involved in the urea cycle, a series of biochemical steps normally required to remove ammonia from the blood. When protein is absorbed and broken down by the body, it produces nitrogen as a waste product. The urea cycle removes nitrogen from the blood and converts it to urea, which is removed from the body through urine. In people with UCDs, nitrogen accumulates and remains in the body as ammonia, which can travel to the brain and cause brain damage, coma or death.
Thursday, February 14, 2013
Subscribe to:
Posts (Atom)